...
首页> 外文期刊>Investigative ophthalmology & visual science >Two AAV2/5-mediated RPGR gene augmentation constructs driven by the GRK1 promoter rescue photoreceptor structure and function in a canine model of RPGR X-linked retinitis pigmentosa
【24h】

Two AAV2/5-mediated RPGR gene augmentation constructs driven by the GRK1 promoter rescue photoreceptor structure and function in a canine model of RPGR X-linked retinitis pigmentosa

机译:由GRK1启动子驱动的两个AAV2 / 5介导的RPGR基因扩增构建物在RPGR X连锁性色素性视网膜色素变性的犬模型中挽救了感光细胞的结构和功能

获取原文

摘要

Purpose : A frameshift mutation in RPGR ORF15 causes an early onset (~ 5 wks of age) and rapidly progressive retinal degeneration in the XLPRA2 dog. Long-term rescue has been achieved by AAV2/5-mediated delivery at early, mid, and late stage disease of a stabilized version of human RPGR cDNA under the control of the IRBP promoter. A 292 nucleotide fragment of the human GRK1 promoter appears to promote transgene expression more efficiently than an IRBP promoter in cones of NHPs. Thus, we now compare the short-term efficacy of two AAV2/5 constructs carrying (under the control of the GRK1 promoter) either a codon-optimized RPGR cDNA (RPGR1) or the same stabilized RPGR cDNA (RPGR2) used in previous canine studies. Methods : Seven XLPRA2 dogs (9 eyes) were treated at ~ 6 wks of age with a subretinal injection (70 ??l; titer: 7.2 x 1011 vg/ml) of either AAV2/5-GRK1-RPGR1 (5 eyes) or AAV2/5-GRK1-RPGR2 (4 eyes) and followed up for either 12 or 18 wks post-injection. Rescue of photoreceptor structure and function was assessed by clinical examination, cSLO/OCT retinal imaging, ERG, and histology/IHC at termination. Results : Both vectors were clinically well tolerated. Rod-mediated ERG function was improved in 4 out of 5 RPGR1-treated eyes and 3 out of 3 RPGR2-treated eyes in comparison to non-injected eyes. At these ages persistent cone-mediated ERG function in untreated eyes precluded accurate assessment of rescue of cone function. Significant and similar preservation of ONL thickness was seen with both constructs in the treated areas of all 9 treated eyes by OCT imaging, and confirmed histologically. IHC revealed that RPGR transgene expression was found predominantly in rods and in rare cones in the treated area of all injected eyes but was associated with improved structure of both rods and cones, and correction of rod and cone opsin mislocalization. Rescue of bipolar cell dendritic arborization abnormalities also was found. Conclusions : In this study rescue of both rods and cones in a canine model of XLRP was achieved following AAV2/5-GRK1-RPGR vector treatment. No significant differences in efficacy were observed when comparing a previously tested stabilized RPGR cDNA to a codon-optimized version. This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.
机译:目的:RPGR ORF15中的移码突变会导致XLPRA2狗的早期发作(约5周龄)并迅速进行视网膜变性。通过在IRBP启动子的控制下,稳定的人RPGR cDNA稳定版本在AAV2 / 5介导的疾病的早期,中期和晚期疾病中实现长期拯救。在NHP视锥细胞中,人GRK1启动子的292个核苷酸片段似乎比IRBP启动子更有效地促进了转基因表达。因此,我们现在比较两种(在GRK1启动子的控制下)携带密码子优化的RPGR cDNA(RPGR1)或先前犬科研究中使用的稳定的RPGR cDNA(RPGR2)的两个AAV2 / 5构建体的短期疗效。方法:7只XLPRA2狗(9只眼)在约6周龄时接受视网膜下注射(70升;效价:7.2 x 1011 vg / ml)AAV2 / 5-GRK1-RPGR1(5只眼)或AAV2 / 5-GRK1-RPGR2(4眼),注射后随访12周或18周。通过临床检查,cSLO / OCT视网膜成像,ERG和终止时的组织学/ IHC评估了感光细胞结构和功能的抢救。结果:两种载体在临床上均耐受良好。与未注射的眼睛相比,杆介导的ERG功能在5只RPGR1处理的眼睛中有4只和3只RPGR2处理的眼睛中有3只得到了改善。在这些年龄段,未经治疗的眼睛中持续的视锥介导的ERG功能妨碍了对视锥功能恢复的准确评估。通过OCT成像,在所有9只治疗的眼睛的治疗区域中,两种构造体均观察到ONL厚度的显着且相似的保留,并且在组织学上得到证实。 IHC揭示了RPGR转基因表达主要在所有注射眼的治疗区域的视杆和视锥中发现,但与视杆和视锥结构的改善以及视杆和视锥蛋白视域错误的纠正有关。还发现了双极细胞树突乔化异常的抢救。结论:在本研究中,在AAV2 / 5-GRK1-RPGR载体处理后,在XLRP犬模型中对杆和锥都进行了抢救。将先前测试的稳定RPGR cDNA与密码子优化版本进行比较时,没有观察到功效的显着差异。这是提交给2016年5月1-5日在华盛顿州西雅图市举行的2016 ARVO年会的摘要。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号